Form 4: Lyell Immunopharma CEO Granted 175,000 Stock Options

Lyell Immunopharma's President and CEO, Lynn Seely, was granted 175,000 stock options and holds 67,571 shares of common stock.

Summary

• Lynn Seely, President and CEO of Lyell Immunopharma, Inc. (LYEL), reported a transaction on October 27, 2025.
• Seely was granted 175,000 derivative securities in the form of options to buy common stock.
• The exercise price for these options is $17.23 per share.
• These options have an expiration date of October 26, 2035.
• The vesting schedule for the options is as follows: 12.5% will vest on April 27, 2026, with the remainder vesting in equal monthly installments over the subsequent 42 months, contingent on continued service.
• Following this transaction, Seely directly beneficially owns 67,571 shares of common stock and 175,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of significant stock options to the CEO is generally a positive signal for executive alignment and retention, indicating confidence in future growth, though it's a standard compensation event rather than a direct operational achievement.

Positives

• The grant of 175,000 stock options to the President and CEO aligns management's incentives with long-term shareholder value creation.
• The vesting schedule, extending over 42 months after an initial 12.5% vest, indicates a commitment to retaining key leadership.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports an executive compensation event.

Risks

• The value of the granted options is subject to the future performance of Lyell Immunopharma's stock price, which carries inherent market risks.
• The vesting of options is contingent on Lynn Seely's continued service, posing a risk if her employment terminates before full vesting.

Future Outlook

The vesting schedule for the granted options extends through April 2026 and then for an additional 42 months, indicating a long-term incentive structure for the CEO tied to future company performance and continued service.

Industry Context

This filing reflects a standard practice in the biotechnology and pharmaceutical industries where executive compensation often includes significant equity components, such as stock options, to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to a CEO is a common compensation practice across the biotechnology and broader corporate landscape, comparable to similar grants observed at companies like Moderna, BioNTech, or Gilead Sciences, where executive compensation packages frequently include substantial equity incentives.
• The vesting schedule, with an initial cliff followed by monthly installments over several years, is a standard mechanism designed to promote executive retention and long-term commitment, consistent with industry benchmarks for executive equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns the CEO's financial interests with long-term shareholder value, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated, but it reinforces the company's executive compensation structure.

Next Steps

• The remaining option shares will vest in equal monthly installments over 42 months following April 27, 2026, subject to Lynn Seely's continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (an option grant) and does not contain information that would fundamentally alter the investment thesis for Lyell Immunopharma. While the alignment of executive incentives is generally positive, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should continue to hold and evaluate the company based on its operational performance, clinical pipeline, and financial results.

Keywords

Lyell Immunopharma, LYEL, Lynn Seely, Stock Options, CEO Compensation, Insider Trading, SEC Form 4, Equity Grant, Biotechnology, Pharmaceuticals